Market closedNon-fractional
Abcellera Biologics/ABCL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Abcellera Biologics
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Ticker
ABCL
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Vancouver, Canada
Employees
586
Website
www.abcellera.com
ABCL Metrics
BasicAdvanced
$912M
Market cap
-
P/E ratio
-$0.51
EPS
0.44
Beta
-
Dividend rate
Price and volume
Market cap
$912M
Beta
0.44
Financial strength
Current ratio
7.761
Quick ratio
7.311
Long term debt to equity
6.025
Total debt to equity
6.515
Management effectiveness
Return on assets (TTM)
-9.59%
Return on equity (TTM)
-12.56%
Valuation
Price to revenue (TTM)
25.156
Price to book
0.81
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-7.023
Growth
Revenue change (TTM)
-80.23%
Earnings per share change (TTM)
185.73%
3-year revenue growth (CAGR)
-56.38%
3-year earnings per share growth (CAGR)
-14.31%
What the Analysts think about ABCL
Analyst Ratings
Majority rating from 9 analysts.
ABCL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.9M
8.79%
Net income
-$41M
-13.80%
Profit margin
-410.10%
-20.77%
ABCL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.11
-$0.10
-$0.17
-$0.14
-
Expected
-$0.13
-$0.13
-$0.13
-$0.17
-$0.14
Surprise
-15.38%
-25.62%
28.57%
-15.79%
-
ABCL News
AllArticlesVideos
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
Business Wire·1 month ago
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
Business Wire·2 months ago
AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abcellera Biologics stock?
Abcellera Biologics (ABCL) has a market cap of $912M as of July 27, 2024.
What is the P/E ratio for Abcellera Biologics stock?
The price to earnings (P/E) ratio for Abcellera Biologics (ABCL) stock is 0 as of July 27, 2024.
Does Abcellera Biologics stock pay dividends?
No, Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Abcellera Biologics dividend payment date?
Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders.
What is the beta indicator for Abcellera Biologics?
Abcellera Biologics (ABCL) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Abcellera Biologics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.